

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFR Wild Type GIST

*Original*

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFR Wild Type GIST / Fiorino, Erika; Merlini, Alessandra; D'Ambrosio, Lorenzo; Cerviere, Ilaria; Berrino, Enrico; Marchiò, Caterina; Giraudo, Lidia; Basiricò, Marco; Massa, Annamaria; Donini, Chiara; Leuci, Valeria; Rotolo, Ramona; Galvagno, Federica; Vitali, Letizia; Proment, Alessia; Ferrone, Soldano; Pisacane, Alberto; Pignochino, Ymera; Aglietta, Massimo; Grignani, Giovanni; Mesiano, Giulia; Sangiolo, Dario. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - ELETTRONICO. - 23:18(2022), p. 10368. [10.3390/ijms231810368]

*Availability:*

This version is available at: 11583/2975747 since: 2023-02-07T13:02:36Z

*Publisher:*

MDPI

*Published*

DOI:10.3390/ijms231810368

*Terms of use:*

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

*Publisher copyright*

(Article begins on next page)



Article

# Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFR Wild Type GIST

Erika Fiorino <sup>1,2</sup>, Alessandra Merlini <sup>1,2,\*</sup>, Lorenzo D'Ambrosio <sup>2,3</sup>, Ilaria Cerviere <sup>2</sup>, Enrico Berrino <sup>1,4</sup>, Caterina Marchiò <sup>1,4</sup>, Lidia Giraudo <sup>1</sup>, Marco Basiricò <sup>1</sup>, Annamaria Massa <sup>1,2</sup>, Chiara Donini <sup>1,2</sup>, Valeria Leuci <sup>1</sup>, Ramona Rotolo <sup>1,2</sup>, Federica Galvagno <sup>1,2</sup>, Letizia Vitali <sup>1,2</sup>, Alessia Proment <sup>1,2</sup>, Soldano Ferrone <sup>5</sup>, Alberto Pisacane <sup>1</sup>, Ymera Pignochino <sup>1,6</sup>, Massimo Aglietta <sup>1,2</sup>, Giovanni Grignani <sup>1</sup>, Giulia Mesiano <sup>1,2,†</sup> and Dario Sangiolo <sup>1,2,\*</sup>

<sup>1</sup> Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, 10060 Candiolo, TO, Italy

<sup>2</sup> Department of Oncology, University of Turin, Regione Gonzole 10, 10043 Orbassano, TO, Italy

<sup>3</sup> Medical Oncology, Azienda Ospedaliera Universitaria S. Luigi, Regione Gonzole 10, 10043 Orbassano, TO, Italy

<sup>4</sup> Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, 10126 Torino, TO, Italy

<sup>5</sup> Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

<sup>6</sup> Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Orbassano, TO, Italy

\* Correspondence: alessandra.merlini@unito.it (A.M.); dario.sangiolo@unito.it (D.S.)

† These authors contributed equally to this work.



**Citation:** Fiorino, E.; Merlini, A.; D'Ambrosio, L.; Cerviere, I.; Berrino, E.; Marchiò, C.; Giraudo, L.; Basiricò, M.; Massa, A.; Donini, C.; et al. Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFR Wild Type GIST. *Int. J. Mol. Sci.* **2022**, *23*, 10368. <https://doi.org/10.3390/ijms231810368>

Academic Editors: Carmine Stolfi and Shinji Miwa

Received: 20 July 2022

Accepted: 30 August 2022

Published: 8 September 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Abstract:** Gastrointestinal stromal tumors (GISTs) are rare, mesenchymal tumors of the gastrointestinal tract, characterized by either KIT or PDGFRA mutation in about 85% of cases. KIT/PDGFR wild type gastrointestinal stromal tumors (wtGIST) account for the remaining 15% of GIST and represent an unmet medical need: their prevalence and potential medical vulnerabilities are not completely defined, and effective therapeutic strategies are still lacking. In this study we set a patient-derived preclinical model of wtGIST to investigate their phenotypic features, along with their susceptibility to cellular immunotherapy with cytokine-induced killer lymphocytes (CIK) and interferons (IFN). We generated 11 wtGIST primary cell lines (wtGISTc). The main CIK ligands (MIC A/B; ULBPs), along with PD-L1/2, were expressed by wtGISTc and the expression of HLA-I molecules was preserved. Patient-derived CIK were capable of intense killing in vitro against wtGISTc resistant to both imatinib and sunitinib. We found that CIK produce a high level of granzyme B, IFN $\alpha$  and IFN $\gamma$ . CIK-conditioned supernatant was responsible for part of the observed tumoricidal effect, along with positive bystander modulatory activities enhancing the expression of PD-L1/2 and HLA-I molecules. IFN $\alpha$ , but not In, had direct antitumor effects on 50% (4/8) of TKI-resistant wtGISTc, positively correlated with the tumor expression of IFN receptors. wtGIST cells that survived IFN $\alpha$  were still sensitive to CIK immunotherapy. Our data support the exploration of CIK immunotherapy in clinical studies for TKI-resistant wtGIST, proposing reevaluation for IFN $\alpha$  within this challenging setting.

**Keywords:** immunotherapy; cytokine-induced killer cells; GIST



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal tumor of the gastrointestinal tract [1–6]. About 85% of GISTs are characterized by either *KIT* or platelet-derived growth factor receptor  $\alpha$  (*PDGFRA*) mutations [4–10]. These can be effectively targeted with tyrosine kinase inhibitors (TKI) approved as different lines of treatment, i.e., imatinib, sunitinib, regorafenib and, in some countries, ripretinib (as first-, second-, third- and fourth-line treatment for advanced GISTs, respectively) [1].

Approximately 15% of GISTs carry neither *KIT* nor *PDGFRA* mutations. These tumors, historically called *KIT*/*PDGFRA* “wild type” GISTs (wtGISTs), represent an unmet diagnostic and therapeutic need and constitute an “umbrella” under which exceedingly rare disease sub-groups with peculiar molecular alterations and genetically so-far uncategorized GISTs are grouped together. In fact, the *KIT*/*PDGFRA* WT GIST classification gathers entities as different as proto-oncogene B-Raf (*BRAF*)-, neurofibromatosis type-1 (*NF1*)-mutated, fibroblast growth factor receptor 1 (*FGFR1*)-, Neurotrophic Receptor Tyrosine Kinase (*NTRK*)-rearranged and succinate dehydrogenase (*SDH*)-deficient GISTs, as well as a number of *KIT*/*PDGFRA* WT GISTs for which no targetable oncogenic driver has been detected yet [1,11,12].

Currently, crucial and open research issues are the exploration of biological/immunological features and potential novel therapeutic vulnerabilities of wtGISTs. The development of hypothesis-driven strategies for wtGISTs requires reliable translational research models, to provide rational knowledge and the basis for clinical studies.

Indeed, the development of immunotherapy has provided a host of opportunities to match novel targets with innovative therapeutic strategies in many cancer types, and GISTs have been no exception to the rule [13–16]. Clinical studies have been developed to investigate immune checkpoint inhibitors (ICI) activity in GISTs combined with TKI, but none of them managed to show evidence of synergism [17,18]. This is possibly due to the fact that imatinib hampers type I IFN production and can decrease HLA-I expression on tumor cells [19], with a potentially detrimental role on the efficiency of ICI due to HLA-I expression reduction [20]; what is more, imatinib can alter intratumoral CD8<sup>+</sup> T-cell subtype composition and activity [21]. Recently, the results of ICI monotherapy with nivolumab vs. nivolumab + ipilimumab in advanced GISTs patients, at least resistant/refractory to imatinib, have been published [22]: the primary endpoint (response rate > 15%) was not met, neither for nivolumab nor for nivolumab + ipilimumab. Hence, disappointingly, in spite of the strong biological rationale, immunotherapy has failed to provide significant survival benefits for advanced GISTs patients so far.

Within this scenario, we set a patient-derived preclinical model with wtGIST to explore a novel approach based on cellular immunotherapy with cytokine-induced killer lymphocytes (CIK), integrated with a re-evaluation of the composite antitumoral role of interferons ( $\alpha$  and  $\gamma$ ) within this setting. CIK are ex vivo expanded T-NK lymphocytes endowed with intense HLA-independent antitumor activity, which has already proved effective in several preclinical reports against various types of solid tumors including sarcomas and GISTs [23–26].


Exploiting HLA-independent cellular therapy allows us to address some main limitations that characterize tumor settings not responsive to checkpoint inhibitors, such as cold microenvironments with poor lymphocyte infiltration and/or reduced or defective antigen presentation. This peculiarity is particularly attractive in wtGISTs that have been reported to present less prominent immune infiltrate compared to *KIT*-mutated GISTs [27], which in turn present fewer immune infiltrating cells with respect to *PDGFRA*-mutated GISTs [28].

Besides the direct tumor killing activity, cellular immunotherapy with CIK may provide indirect beneficial effects, inflaming the tumor microenvironment and supplying important cytokines, such as type I interferons (IFNs). The potential antitumor activities of IFNs are of particular interest and should be re-evaluated, especially in the context of combinatorial strategies that might exploit their immunomodulatory effects. Evidence of such activities, in combination with a favorable safety profile, has been reported for IFN $\alpha$  in a phase II study for patients with advanced GISTs (NCT00585221) [29–32]. Here we focused on both CIK activity and the direct cytotoxic and indirect modulatory effects of IFNs within our wtGIST model, to highlight mechanistic insights and therapeutic opportunities to be envisioned in the context of combinatorial strategies for GISTs not responsive to targeted therapies.

## 2. Results

### 2.1. Generation and Characterization of Primary Cell Lines from Patients with Diagnosis of *KIT/PDGFR* WT GIST

We set a preclinical experimental platform based on primary cell lines derived from patients with a pathologic diagnosis of *KIT/PDGFR* wtGIST. A study schematic of the experimental workflow is provided in Supplementary Figure S1. Mutational analysis of 38 GIST patients at diagnosis ( $n = 19$  affected by advanced GIST and  $n = 19$  with localized disease) identified *KIT/PDGFR* mutations in 33 patients (87%), while the remaining 5 resulted *KIT/PDGFR* WT (13%). Twenty-five out of the 33 patients with *KIT/PDGFR*-mutated GIST at diagnosis underwent at least one line of systemic treatment with imatinib, sunitinib—or both—before surgery. Among these, in 13 out of the 25 patients the same mutational status detected at diagnosis was found after analysis of the surgical specimen while, in the remaining 12 patients' cases, the surgical specimen (although showing adequate cellularity and by selecting only vital areas) resulted *KIT/PDGFR* WT. The latter 12 patients had received significantly longer treatment courses (mean treatment duration: 26 months) with respect to cases in which the mutation was maintained (mean treatment duration: 9 months) (Figure 1).



**Figure 1.** Schematic summary of the experimental platform from GIST patients. m = months.


We confirmed by pathology evaluation that the *KIT/PDGFR* WT GIST samples had positive immunostaining for KIT (CD117)/DOG1 (Figure 2) and did not display dedifferentiation features. From this cohort, we successfully generated 11 primary cell lines of *KIT/PDGFR* WT GIST (wtGISTc). Primary cell lines showed morphological features and IHC patterns consistent with the pathology evaluation of the corresponding tumors (Figure 2).

We confirmed the genetic consistency between wtGISTc ( $n = 11$ ) and their original surgical samples by DNA sequencing. All wtGISTc resulted *KIT/PDGFR* WT; additional genetic alterations, detected by using a targeted panel of 523 cancer-related genes, are shown in Table 1.

As further characterization, we confirmed the conserved HLA-I membrane expression by our wtGISTc. We reported the expression rate for the inhibitory immune-checkpoints molecules PD-L1 ( $38 \pm 7\%$ ) and PD-L2 ( $28 \pm 6\%$ ), as shown in Supplementary Figure S2, along with the main target molecules (NKG2D ligands) recognized by CIK lymphocytes (ULPBPs 2/5/6 =  $59 \pm 4\%$  and MICA A/B =  $15 \pm 5\%$ ). A negligible expression was detected for the DNAM-1 ligands, CD112 and CD155. The tumorigenic potential in vivo of wtGISTc was confirmed ( $n = 8$ ) in immunodeficient mice, with a mean time of engraftment of 6 weeks.


**Table 1.** Mutational profile of wtGISTc as assessed by targeted sequencing. VAF: Variant Allele Frequency.

wtGISTc	Gene Name	Variant Type	Single Nucleotide Variant ID	VAF (%)	Fold Change
S012	SPEN	inframe_deletion	chr1_16260673_CCTCACTGGTCTGGTGAGCGCA_C	27	
	LATS2	missense_variant	chr13_21562627_G_A	36	
	JAK2	amplification	chr9		1.946
	PTEN	amplification	chr10		1.445
S061	/	/	/	/	
S075	/	/	/	/	
S108	NOTCH1	missense variant:splice region variant	chr9_139401170_G_A	51	
S125	/	/	/	/	
S148	ARID1B	missense_variant	chr6_157100551_G_C	47	
	PRKDC	missense_variant	chr8_48805728_C_G	24	
S173	MYCN	missense_variant	chr2_16082319_C_T	20	
	GNAS	missense_variant	chr20_57474036_G_T	19	
S188	PGR	missense_variant	chr11_100998322_C_G	31	
S220	HIST3H3	missense_variant	chr1_228612992_G_A	16	
	LRP1B	missense_variant	chr2_141201961_G_T	19	
	CUL3	missense_variant	chr2_225379486_G_A	20	
	PRKDC	missense_variant	chr8_48866988_T_G	58	
	MALT1	missense_variant	chr18_56363602_A_G	16	
	NF2	stop_gained	chr22_30038226_C_A	50	
	FGFR1	amplification	chr8		1.533
	MYC	amplification	chr8		1.637
S243	IRS1	stop_gained	chr2_227661875_G_T	9	
	PDGFRB	inframe_deletion	chr5_149495390_AGCTCTG_A	7	
	NOTCH4	missense_variant	chr6_32189007_G_A	7	
S288	FGF2	missense_variant	chr4_123813429_C_T	51	
	FAT1	missense_variant	chr4_187628598_T_C	46	

**Figure 2.** CD117 and DOG1 expression in GIST samples and corresponding wtGISTc. CD117 (A) and DOG1 (B) immunohistochemistry staining (magnification 40×) in two representative surgical samples from GIST patients (diffuse expression on the left, focal expression on the right) and the corresponding wtGISTc. S012 and S108: unique patient numbers.

### 2.2. wtGISTc Are Resistant to Imatinib and Moderately Sensitive to Sunitinib

We explored in vitro the sensitivity of wtGISTc to imatinib and sunitinib. All the wtGISTc ( $n = 11$ ) were resistant to imatinib. Treatment of wtGISTc with high doses of imatinib, ranging from 5 to 25  $\mu\text{M}$ , resulted in a mean  $\text{IC}_{50}$  dose of  $17 \pm 8 \mu\text{M}$  ( $n = 20$  Figure 3A). wtGISTc resulted only moderately sensitive to sunitinib ( $n = 37$ , Figure 3B) with a mean  $\text{IC}_{50}$  dose of  $6 \pm 2 \mu\text{M}$ , if compared to sensitive control (A498 RCC line,  $\text{IC}_{50}$  5  $\mu\text{M}$ ).



**Figure 3.** Sensitivity to imatinib and sunitinib of wtGISTc in vitro. wtGISTc resulted resistant to imatinib ( $\text{IC}_{50}$   $17 \pm 8 \mu\text{M}$ , mean  $\pm$  SEM) (A) and moderately sensitive to sunitinib ( $\text{IC}_{50}$   $6 \pm 2 \mu\text{M}$ , mean  $\pm$  SEM) (B). A498 RCC line was used as a positive control of sunitinib sensitivity.


### 2.3. Generation and Characterization of CIK Lymphocytes from GIST Patients

CIK were successfully generated and expanded ex vivo starting from PBMC of 13 patients with GIST. The median expansion fold was 184 (31–1258), a good percentage of mature CIK was  $\text{CD}3^+\text{CD}56^+$  with a median value of 43% (24–60). Mature CIK were mainly  $\text{CD}8^+$  with a median value of 81% (64–91). As expected, the receptors NKG2D and DNAM-1 were highly expressed by mature CIK with a median value of 86% (40–92) and 94% (86–100), respectively. The percentage of NK cells in the bulk CIK population was negligible. Representative dot plots with phenotype of mature CIK are reported in Figure 4A. At the end of the ex vivo expansion, the different lymphocyte subsets in bulk CIK ( $n = 13$ ) were the effector memory (EM:  $\text{CD}62\text{L}^-\text{CD}45\text{RA}^-$   $61 \pm 3\%$ ) (Figure 4B,  $n = 32$ ). We observed a low membrane expression of  $\text{PD-1}^{\text{high}}$  ( $4 \pm 2\%$ ), and  $\text{LAG}3^{\text{high}}$  ( $5 \pm 1\%$ ) expression on a low percentage of cells, while TIM3 ( $96 \pm 1\%$ ), and TIGIT ( $92 \pm 1\%$ ) were expressed on a high percentage of cells, as shown in Supplementary Figure S3.

### 2.4. CIK Are Capable of Direct and Indirect Cancer Cell Killing and Immunomodulation in wtGISTc Resistant to TKI

We explored the cytotoxic activity of patient-derived CIK ( $n = 12$ ) against wtGISTc ( $n = 9$ ) resistant to imatinib. In 4/9 cases we were able to set up an autologous match as the target (wtGISTc) and the effectors (CIK) were derived from the same patients. CIK efficiently killed wtGISTc, with a specific cancer cell lysis of  $62 \pm 2.3\%$ ,  $45 \pm 3.1\%$ ,  $30 \pm 3.2\%$  and  $18 \pm 2.8\%$  at progressively decreasing effector/target ratios (10:1, 5:1, 2.5:1 and 1:1, respectively). In selected experiments ( $n = 4$ ) we confirmed that CIK retained their full anti-tumor potential even when sequentially tested against wtGIST cells that survived treatment with sunitinib in vitro ( $\text{IC}_{50}$  dose, Figure 5A). Besides the direct CIK-mediated cytotoxicity, we questioned and explored the indirect activities that CIK may exert against wtGISTc through the secretion of soluble factors, intended either as tumoricidal or immunomodulatory effects. First, we observed that CIK-conditioned supernatant, collected at the end

of cancer cell killing assays, was capable of killing wtGISTc (mean cancer cell specific mortality  $35 \pm 2\%$ ) (Figure 5B). Furthermore, CIK-conditioned medium also significantly enhanced HLA-I (2-fold) and  $\beta$ 2-microglobulin (B2M)-2.7-fold) membrane expression on wtGISTc ( $n = 4$ ) (Figure 5C,D). Consistently, we observed the enhanced HLA-I/B2M expression also in the residual wtGIST cells collected at the end of the cytotoxicity assays with CIK lymphocytes, supporting a potentially relevant bystander immunomodulatory effect following CIK cellular immunotherapy. The analysis by ELISA of the CIK-conditioned medium, always collected at the end of 72 h cancer cell killing assays ( $n = 6$ ), confirmed an intense production of protease granzyme B along with IFN $\alpha$  and IFN $\gamma$  (Figure 5E).




**Figure 4.** Phenotype and main subsets of patient-derived CIK lymphocytes. Representative phenotype of CIK at the end of their ex vivo expansion; mature CIK were mainly CD3<sup>+</sup>CD8<sup>+</sup> with a relevant CD3<sup>+</sup>CD56<sup>+</sup> double-positive subset. The receptors mostly imputed to cancer cell recognition, NKG2D and DNAM-1, were expressed on a high percentage of cells (A). Distribution of main lymphocyte subsets with effector memory (EM), effector memory-RA<sup>+</sup> (EM RA), central memory (CM), and naïve (B).


### 2.5. Antitumor and Immunomodulatory Activity of IFN $\alpha$ and IFN $\gamma$ in wtGISTc

While granzyme B was expected as one of the main mediators of CIK cytotoxicity, we focused on the observed presence of IFNs, as these cytokines may be of particular relevance in this context, considering their past empirical consideration in GIST clinical studies [29]. We assessed the tumoricidal and immunomodulatory effects of IFN $\alpha$  and IFN $\gamma$  on our wtGISTc resistant to TKI. IFN $\alpha$  ( $1 \times 10^4$  IU/mL) was capable of direct cancer cell cytotoxicity in 4/8 (50%) of wtGISTc tested, while no significant cancer cell cytotoxicity was mediated by IFN $\gamma$  ( $1 \times 10^3$  IU/mL) (Figure 6).

Both IFN-sensitive and resistant wtGISTc retained their in vitro susceptibility to CIK mediated killing, as demonstrated by sequential treatments (not shown). We confirmed by qRT-PCR the expression of IFN $\alpha$ R1 and IFN $\gamma$ R1 in wtGISTc ( $n = 8$ ), observing their higher levels among wtGISTc sensitive to IFN $\alpha$  (Figure 7B).




**Figure 5.** (A) Antitumor activity of CIK against wtGISTc resistant to TKI. Patient-derived CIK efficiently killed in vitro wtGISTc resistant to imatinib. The CIK killing ability was retained when sequentially tested against wtGISTc that survived treatment with sunitinib. (B) CIK-conditioned medium is endowed with tumoricidal activity against wtGISTc in vitro. CIK-conditioned supernatants, collected after 72 h co-culture of CIK with wtGISTc, was shown to be capable of cancer cell killing activity even in the absence of a direct CIK-tumor contact. (C,D) Direct and indirect modulation of HLA-I and  $\beta$ 2M in wtGISTc by CIK lymphocytes. The membrane expression of both HLA-I (C) and  $\beta$ 2M (D) on wtGISTc was enhanced after treatment with CIK or CIK-conditioned medium (\*  $p < 0.05$ ; \*\*  $p < 0.005$ , nonparametric  $t$ -test). (E) Soluble factors produced by activated CIK lymphocytes. Granzyme B,  $IFN\alpha$  and  $IFN\gamma$  are intensely produced by CIK following contact with wtGISTc (10:1 E:T).




**Figure 6.** Sensitivity of wtGISTc to  $IFN\alpha$  and  $IFN\gamma$ . After treatment, all wtGISTc resulted resistant to  $IFN\gamma$  and 4 out of 8 wtGISTc were relatively sensitive to  $IFN\alpha$  (mean tumor cell death 42%).





**Figure 7.** IFN $\alpha$  and IFN $\gamma$  receptors (subunit 1) in wtGISTc. wtGISTc were confirmed to express IFN $\alpha/\gamma$  R1 even if at a lower level than monocytes, used as positive controls (A). The expression levels of IFN $\alpha$ R1 mRNA were significantly higher in wtGISTc sensitive to IFN $\alpha$  (B). All values are represented in fold change and normalized on three housekeeping genes (GAPDH, HPRT and PGK). (\*\*\*)  $p < 0.001$ , nonparametric  $t$ -test).

Along with the reported direct tumoricidal effect, we observed that treating wtGISTc ( $n = 8$ ) in vitro with both IFN $\alpha$  and IFN $\gamma$  resulted in potentially relevant immunomodulatory effects. Namely, we observed a significantly enhanced membrane expression of HLA-I/B2M molecules and immune checkpoints PD-L1 and PD-L2 (Figure 8A–D).



**Figure 8.** Modulation of HLA-I,  $\beta$ 2-microglobulin, PD-L1 and PD-L2 expression mediated by IFNs in wtGISTc. IFNs determined a significant enhancement in the expression of HLA-I/B2M and immune checkpoints (PDL-1/2) in wtGISTc. All the reported values were compared to untreated controls and expressed in MFI. (\*\*\*\*)  $p < 0.0001$ ; (\*\*)  $p < 0.005$ ; (\*)  $p < 0.05$ ; nonparametric  $t$ -test).

### 3. Discussion

In our study we explored and report the preclinical vulnerability of *KIT/PDGFR* WT GISTs to cellular immunotherapy with CIK lymphocytes, highlighting potentially relevant

antitumor and immunomodulatory effects that prompt new considerations on the role of IFNs in this challenging setting.

Studying the peculiar biological features of wtGIST, along with the exploration of effective therapeutic interventions, requires the availability of reliable investigational/experimental models. To this end, our patient-derived platform provides a reliable approximation of realistic scenarios, allowing the acquisition of new, important immune-profiling information on wtGIST and explorative therapeutic opportunities. As a first consideration, the observed prevalence of wtGIST, either primitive or emerging after prolonged imatinib treatment, supports clinical reflections on the opportunity to repeat biopsies to reevaluate the molecular profiling of GIST at the time of disease progression. Small case series have reported KIT expression loss after imatinib treatment [33]; nonetheless, whether mutational re-testing is necessary at every surgical intervention/at every disease progression is not yet defined, even in international guidelines. Second, the preserved expression of HLA-I molecules on wtGIST cells, and their upregulation upon treatment with CIK or IFNs, is indicative of an indirect positive immunomodulatory effect of such treatments that could trigger activities from the adaptive immune response [20].

It is important to note that the *in vitro* dose of IFN $\alpha$  used in our experiments ( $1 \times 10^4$  IU/mL) is a much higher concentration as compared with the reported spontaneous CIK production that is, however, still capable of inducing immunomodulatory effects. Considering the future design of clinical trials in combination with cellular immunotherapy, it is conceivable that different and even lower ranges of IFN $\alpha$  may be tested with the intent of mainly exploiting its immunomodulatory effect while reducing potential toxicities.

The modulatory activity exerted by IFNs is associated with the expression of regulatory immune checkpoints (PD-L1/2), as confirmed by our data. On one side, this could contribute to the immune escape of wtGIST, as recently reported by Vitiello et al. [28], but also set a conceptual frameshift to envision possible synergisms with checkpoint inhibitors [34–36]. Finally, the phenotypic profiling of wtGIST confirms the proficient expression of stress-inducible molecules that mechanistically substantiate the observed activity of CIK lymphocytes and underscores the potentialities, either endogenous or therapeutically induced, of effectors from the innate immune system in this challenging setting.

In previous works, we reported the intense activity of CIK against multiple types of soft tissue sarcomas, including GIST [23]. The relevance of the present report is the evidence that patient-derived CIK retain their potentialities even within the peculiar wtGIST setting, resistant to TKIs. The observed tumoricidal effects by CIK against wtGIST cells that survived a pretreatment with either sunitinib or IFNs underscore their potential role in the treatment of drug-resistant *KIT/PDGFR* WT GISTs.

A possible limitation may be seen in the fact that our study did not include *in vivo* experiments. In previous works, we reported the pharmacodynamic properties and tumor recruitment capabilities of CIK lymphocytes *in vivo*. A tumor xenograft model in immunodeficient mice would not add much substance to the main core findings of the present study, where the exploration of the integrated direct and indirect immunomodulatory activities of CIK and IFNs would require a complex immune-competent model. Based on the described preclinical data, the best next experimental steps should be probably designed within controlled clinical studies that could benefit from the already existing knowledge of previous trials with IFN $\alpha$  in GIST patients, and from the safety and pharmacodynamic information with CIK in various tumor settings. Our findings highlight and propose also a new perspective on the therapeutic role of IFN $\alpha$  in wtGISTs that are resistant (or progressed) to conventional TKI treatments. We provide experimental evidence that IFN $\alpha$  may exert a direct cytotoxicity on wtGIST cells, resistant to imatinib, along with important immunomodulatory effects that could reactivate the individual adaptive immune response or offer opportunities for synergism with checkpoint inhibitors, as ongoing trials are currently exploring.

Of note is that the observed positive correlation between the membrane expression of IFNR1 on wtGIST and their sensitivity to IFN $\alpha$  may raise both biological and clinical

considerations. On one side, it could have a predictive role while, on the other one, it provides a rationale to explore molecular strategies that could restore its expression.

Overall, our findings highlight the need for the molecular re-evaluation of GIST at disease progression and support the exploration of CIK cellular immunotherapy in clinical studies for patients with TKI-resistant, *KIT/PDGFR*A wild type GIST. A reappraisal and reinterpretation of the role of IFN $\alpha$ , either as monotherapy or in the context of integrated immunotherapy approaches, emerges and warrants clinical consideration.

#### 4. Materials and Methods

##### 4.1. Experimental Platform and Generation of Wild-Type Primary GIST Cell Lines

Our tumor samples, primary cell lines and cultures were generated from biopsies obtained from patients with confirmed diagnoses of GIST. All patients gave informed consent for the collection and use of their biological material for research purposes, approved by the ethics committee. All surgical samples were analyzed for c-KIT (exons 9,10,11,13 and 17) and PDGFRA (exons 12,14 and 18) mutations. Primary wild-type GIST cultures (wtGISTc) were generated, starting from surgical samples, by mechanical (scalpel) dissection and enzymatic digestion with type I collagenase (Invitrogen, Carlsbad, CA, USA) or by the gentleMACS instrument (Miltenyi Biotec, Bologna, Italy) using the specific human tumor dissociation kit. Tumor cells were resuspended in Iscove's Modified Dulbecco's Medium (IMDM, Sigma Aldrich, Saint Louis, MO, USA) with 15% heat-inactivated Fetal Bovine Serum (Euroclone Spa, Milan, Italy), penicillin and streptomycin (100 U/mL, Sigma Aldrich, Saint Louis, MO, USA), L-glutamine (2 mM, Sigma Aldrich, Saint Louis, MO, USA) and seeded in plates treated for anchorage-dependent cultures (Corning/Costar, VWR International PBI s.r.l., Milan, Italy) at standard conditions of 37 °C and 5% CO<sub>2</sub>. All cell cultures obtained were analyzed for c-KIT (exons 9,10,11,13 and 17) and PDGFRA (exons 12, 14 and 18) mutations by Real-time qPCR (RT-qPCR) to confirm the conformity with the mutational status of original surgical samples. In vivo assays were conducted to confirm the tumorigenicity of wtGISTc:  $1 \times 10^6$  tumor cells re-suspended in 200  $\mu$ L of a 1:1 mix of PBS 1 $\times$  and Matrigel Basement Membrane Matrix (Sigma Aldrich, Saint Louis, MO, USA) were implanted subcutaneously in six-week-old NOD/LtSz-scid/scid (NOD/SCID; Charles River Laboratories, Calco, Italy) female mice. Tumor growth was monitored weekly with calipers and mice were sacrificed when tumors reached a maximum main diameter of 2 cm.

##### 4.2. CIK Cells Culture and Ex Vivo Expansion

CIK cells were expanded from fresh or cryopreserved peripheral blood mononuclear cells (PBMC) from 13 patients with confirmed GIST diagnoses. All patients gave informed consent for the collection and use of their biological material for research purposes, approved by the ethics committee. PBMC were separated by density gradient centrifugation (Lymphoprep, Aurogene s.r.l., Rome, Italy) and seeded into cell culture flasks ( $2 \times 10^6$  cells/mL) in RPMI-1640 medium (Gibco BRL Life Technologies, Monza, Italy) supplemented with 10% heat-inactivated fetal bovine serum (Sigma Aldrich, Saint Louis, MO, USA), penicillin and streptomycin (100 U/mL, Gibco BRL Life Technologies, Italy), L-glutamine (2 mM, Sigma Aldrich, Saint Louis, MO, USA) at 37 °C and 5% CO<sub>2</sub>. IFN $\gamma$  (1000 U/mL, Miltenyi Biotec, Bologna, Italy) was added on day 0; after 24 h, recombinant human interleukin IL-2 (300 U/mL, Miltenyi Biotec, Bologna, Italy) and anti-CD3 antibody (50 ng/mL, MACS Miltenyi Biotec, Bologna, Italy) were added. Cells were ex vivo expanded for 3 weeks. Fresh medium and IL-2 (300 U/mL) were added every 3 days, and the cell concentration was maintained at  $2-1.5 \times 10^6$  cells/mL.

##### 4.3. Flow Cytometry

To evaluate phenotype features, wtGISTc and CIK were labeled and acquired on a FACS Cyan (CyAN ADP, Beckman Coulter s.r.l., Cassina de' Pecchi, Italy). Flow cytometry data were analyzed using Summit Software (Beckman Coulter s.r.l., Cassina de' Pecchi, Italy). wtGISTc were stained with the following fluorescein isothiocyanate (FITC), phyco-

erythrin (PE)-, or allophycocyanin (APC)-conjugated mouse monoclonal antibodies (mAbs): MICA/B and ULBP1, ULBP2, 5, 6 and ULPB3 for the NKG2D ligands (Pharmingen, Milan, Italy), CD112 and CD155 (R&D Systems, Minneapolis, MN, USA) for DNAM ligands and PD-L1 and PD-L2 (Pharmingen, Milan, Italy). HLA-I and  $\beta$ 2-microglobulin (in collaboration with Soldano Ferrone, clones TP25.99.8.4 [37] and L368 [38], respectively), and Human IFN $\alpha$ / $\beta$  R1 and IFN $\gamma$  R1/CD119 Antibody (R&D Systems, Minneapolis, MN) were detected on wtGISTc with the use of a secondary antibody (Goat Anti-Mouse Ig, Pharmigen, Milan, Italy). Conjugated anti-human monoclonal antibodies for CD3 (Pharmingen, Milan, Italy), CD8, CD56, NKG2D, CD62L, CD45RA, PD-1, TIM-3 (MACS Miltenyi Biotec, Bologna Italy), DNAM-1, LAG3 (BD Biosciences, Milan Italy), TIGIT (eBiosciences, San Diego, CA, USA), NKp30, NKp44 and NKp46 (MACS Miltenyi Biotec, Bologna, Italy) were used to characterize CIK.

#### 4.4. mRNA Analysis

Total RNA automatic extraction of wtGISTc was performed using the Maxwell RSC miRNA Tissue KIT and Maxwell RSC Instrument (Promega, Milan, Italy), according to the manufacturer's instructions. The RNA was reverse-transcribed into cDNA by a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems by ThermoFisher Scientific, Rodano, Italy) and quantified with a Nanodrop spectrophotometer (The DeNovix DS-11 FX Series). cDNA was amplified by RT-qPCR using a SYBR<sup>®</sup> Green Master Mix probe (Advanced Universal SYBR Green Master Mix, Biorad, Segrate, Italy). Specific primers for subunit 1 of IFN $\alpha$  and IFN $\gamma$  receptor genes were used: IFN $\alpha$  receptor forward 5'-CATCACGTCATACCAGCCATTT-3', reverse 5'-CTGGATTGTCTTCGGTATGCAT-3'; IFN $\gamma$  receptor forward 5'-GCGCCTGTTGTCTTAGCTAC-3', reverse 5'-CTCATCCAATGCAAGTCCGG-3'. Data analyses were conducted, comparing the expression of IFN $\alpha$  and IFN $\gamma$  receptors in wtGISTc and monocytes (positive controls). The gene expression levels were normalized to three different housekeeping genes' (GAPDH, PGK and HPRT) expression and reported as fold change. The monocytes were separated from the PBMC with human CD14 microbeads (MACS Miltenyi Biotec, Bologna, Italy), according to manufacturer's instructions.

#### 4.5. DNA Sequencing Analysis and Gene Mutation Profile

Genomic DNA for each sample underwent deep sequencing using the Illumina TruSight Oncology 500 panel (Illumina, Milan, Italy). The targeted panel was 1.94 Mb in size, encompassing the exon sequences of 523 cancer-related genes (coding size 1.2 Mb). The MSI status of approximately 120 loci and the tumor mutation burden were also assessed by the panel. Following the manufacturer's protocol, the DNAs were sonicated using the Covaris Focused-ultrasonicator (Covaris, Woburn, MA, USA), the UMIs adapted and then indexed. Two rounds of hybrid-capture allowed an enrichment of the targeted sequence. The libraries were then sequenced on the Illumina-NovaSeq 6000 instrument (Illumina, Milan, Italy) to reach a minimum of 500 $\times$  read depth. Raw data were processed by the Illumina Local App associated with the TSO500 panel (TruSight Oncology 500 v2.2 Local App) to produce FASTQ files through the alignment of the sequence to the human reference sequence GRCh37 (hg19). The Local App also performed sequencing QCs and somatic variant-calling with a tumor-only pipeline. We confirmed the mutational status for both KIT and PDGFRA genes using the mass spectrometry matrix-assisted laser desorption ionization time-of-flight method (Maldi-TOF) on the MassARRAY System (Agena Bioscience, San Diego, CA, USA) with the Myriapod<sup>®</sup> GIST primer set (cod. SQ030) (Diatech Pharmacogenetics, Jesi, Italy). A small aliquot of DNA was amplified with the specific primer set encompassing the KIT and PDGFRA regions covered by the panel. After the purification of the PCR products, a single base extension was applied, and the mass of the single-based extended primers was checked with the Maldi-TOF method. Mass spectra were analyzed with the MassARRAY<sup>®</sup> Analyzer 4 software (Agena Bioscience, Lincoln, NE, USA).

#### 4.6. *In Vitro* Drug Sensitivity and Cancer Cell Killing Assays

To assess the sensitivity of wtGISTc to target therapy and interferons' direct cytotoxic activity, tumor cells were seeded in 96-multiwell plates (Corning/Costar, VWR International PBI s.r.l., Milan, Italy). After 24 h, the cells were treated with scalar doses of imatinib (Selleckem, Houston, TX, USA) from 5  $\mu$ M to 25  $\mu$ M, sunitinib (Selleckem, Houston, TX, USA) from 0,1  $\mu$ M to 15  $\mu$ M, IFN $\alpha$  ( $1 \times 10^4$  IU/mL, Myltenyi Biotec, Bologna, Italy) or IFN $\gamma$  ( $1 \times 10^3$  IU/mL, Peprotech, Neuilly-sur-Seine, France). The A498 renal cancer carcinoma (ACC) cell line was used as the control for sunitinib sensitivity (IC<sub>50</sub> 5  $\mu$ M). To study the therapeutic combination between the imatinib/sunitinib and the IFN $\alpha$ /IFN $\gamma$ , wtGISTc were seeded in 96-multiwell plates (Corning/Costar, VWR International PBI s.r.l., Milan, Italy) in triplicate and, after 24 h, were treated with imatinib (therapeutic dose 25 nM), sunitinib (IC<sub>50</sub> dose) IFN $\alpha$  ( $1 \times 10^4$  IU/mL) and IFN $\gamma$  ( $1 \times 10^3$  IU/mL) alone or in combination. The tumor cell lysis was assessed with the CellTiter-Glo<sup>®</sup> Luminescent Cell Viability Assay (Promega, Milan, Italy), according to the manufacturer's instructions. The luminescence signal was determined with a microplate reader (Multi-Mode microplate Readers Biotek SRL, Milan, Italy), indicating the number of viable and metabolically-active target cells by quantifying the ATP. The IC<sub>50</sub> doses (imatinib and sunitinib) correspond to IC values ranging between 40% and 60%. The wtGISTc were considered IFNs-sensitive if the mortality after exposure resulted greater or equal to 25%; otherwise, they were considered resistant. The percentages of tumor lysis were evaluated after 72 h of each treatment. The wtGISTc treated with an equal volume of cell culture medium alone was used as the control. To assess IFN $\alpha$  and IFN $\gamma$  immunomodulatory activity, wtGISTc were seeded in 6-multiwell plates and after 24 h, treated with IFN $\alpha$  ( $1 \times 10^4$  IU/mL, Myltenyi Biotec, Bologna, Italy) or IFN $\gamma$  ( $1 \times 10^3$  IU/mL, Peprotech, Neuilly-sur-Seine, France) for 72 h at 37 °C and 5% CO<sub>2</sub>. Tumor cells were detached with Stem Pro Accutase Cell Dissociation Reagent (ThermoFisher Scientific, Waltham, MA, USA) and stained with mAb for flow cytometry, as previously described. We assessed the tumor-killing abilities of patient-derived CIK *in vitro* against wtGISTc. Cytotoxicity assays against the wtGISTc were performed using flow cytometry or a bioluminescent cell viability assay. For the flow cytometry assays, the target cells were stained with the vital dye PKH26 kit (Sigma-Aldrich, Saint Louis, MO, USA), according to the manufacturer's protocol. The immune-mediated killing was analyzed with flow cytometry (Cyan ADP, Dako, Milan, Italy) and measured by the DAPI permeability of the target cells (PKH26<sup>+</sup> gate). In selected experiments, immune-molecules modulation on the wtGISTc by CIK was evaluated by flow cytometry. For the bioluminescent method, the cytotoxicity was measured with the CellTiter-Glo<sup>®</sup> Luminescent Cell Viability Assay (Promega, Milan, Italy), previously described. CIK cells were co-cultured at different effector:target ratios (10:1, 5:1, 2.5:1 and 1:1) in cytotoxicity assays (300 U/mL IL-2 medium at 37 °C and 5% CO<sub>2</sub>) for 72 h. In selected experiments, we tested CIK cytotoxicity against the wtGISTc after molecular targeted therapy and interferons exposure. To study the indirect cytotoxic activity, in selected experiments, the CIK-conditioned supernatant was collected at the end of the tumor killing assays at effector:target ratio 10:1. Indirect cytotoxicity assays of CIK-conditioned supernatant against the wtGISTc were performed using flow cytometry, after 72 h exposure. To assess the CIK-conditioned supernatant immunomodulatory activity, after 72 h, the wtGISTc were labeled with mAb and the immune molecules were evaluated by flow cytometry, as previously described. The internal control target cells were tested alone, separately from the CIK, to assess spontaneous mortality. The percentage of wtGISTc-specific lysis for each effector:target cell ratio was calculated using the following formula: [(experimental – spontaneous mortality) / (100 – spontaneous mortality)]  $\times$  100].

#### 4.7. *In Vitro* Soluble Factors Production

To quantify the release of soluble factors, the CIK cells were co-cultured with tumor targets in RPMI with 300 U/mL IL-2 at a 10:1 effector:target ratio, incubated at 37 °C for 72 h and then the cell culture supernatant was collected. The Human Luminex Discovery Assay (R&D System, Milan, Italy) was used to measure the IFN $\alpha$  and Granzyme-B production.

Data were acquired and analyzed by Bioclarma (Analysis Service). The IFN $\gamma$  concentration was evaluated in the cell culture supernatant with the Human IFN- $\gamma$  ELISA Kit (Diaclone, Besançon, France), according to the manufacturer's instructions. Each sample was measured in duplicate and all data were analyzed and reported following their normalization on spontaneous cytokines production by effectors and targets alone.

#### 4.8. Statistical Analysis

All the experiments were performed at a minimum as duplicates. The data were analyzed using the GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA). Descriptive data are presented as mean  $\pm$  SEM or median with related ranges. To find statistical significance in the comparison of two groups, we relied on two-tailed Student's *t*-tests; for comparison of three or more groups, the data were analyzed by two-way ANOVA with Kruskal–Wallis test multiple comparisons. A *p*-value  $< 0.05$  was considered significant. Significance is represented on graphs as \* *p*  $< 0.05$ , \*\* *p*  $< 0.01$ , \*\*\* *p*  $< 0.001$  and \*\*\*\* *p*  $< 0.0001$ .

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms231810368/s1>.

**Author Contributions:** E.F., A.M. (Alessandra Merlini), L.D., G.G., G.M., D.S.: conceptualization; E.F., G.M.; methodology; E.F., G.M.; formal analysis; E.F., A.M. (Alessandra Merlini); E.B., C.M., L.G., M.B., A.M. (Annamaria Massa), C.D., V.L., R.R., F.G., L.V., A.P. (Alessia Proment), S.F., A.P. (Alberto Pisacane), Y.P., A.M. (Annamaria Massa), G.G., G.M., D.S.: investigation; E.F., G.M.; D.S.: resources; E.F., A.M. (Alessandra Merlini), E.B., I.C., C.M., L.G., M.B., A.M. (Annamaria Massa), C.D., V.L., R.R., F.G., L.V., A.P. (Alessia Proment), S.F., A.P. (Alberto Pisacane), Y.P., M.A., G.G., G.M., D.S.: data curation; E.F., A.M. (Alessandra Merlini), G.M., D.S.; writing—original draft preparation; E.F., A.M. (Alessandra Merlini), L.D., E.B., I.C., C.M., L.G., M.B., A.M. (Annamaria Massa), C.D., V.L., R.R., F.G., L.V., A.P. (Alessia Proment), S.F., A.P. (Alberto Pisacane), Y.P., M.A., G.G., G.M., D.S.: writing—review and editing; E.F., A.M. (Alessandra Merlini), L.D., G.M., D.S.: visualization; G.M., D.S.: supervision; G.M., D.S.: project administration; Y.P., G.G., D.S.: funding acquisition. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by AIRC IG 2017-ID. 20259 (D.S.); RC 2022 Ministero della Salute (G.Gr.); AIRC IG 2019-ID 23104 (G.G.); FPRC 5  $\times$  1000 Ministero della Salute 2015 ImGen (G.G. and D.S.); FPRC 5xmille MIUR 2014 (G.G.); Ministero della Salute-Ricerca Finalizzata, Giovani Ricercatori GR-2016-02362726 (Y.P.); Fondazione per la ricerca sui tumori dell'apparato muscoloscheletrico e rari ONLUS CRT RF = 2016–0917; NIH grants RO1CA230275 and RO1DE028172 (S.F.).

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board and Ethics Committee of Candiolo Cancer Institute, FPO-IRCCS (296-2020; date 14-OCT-2020). For the animal studies: authorization by the Italian Ministry of Health (Prot. 21635.18, Aut.Min.834/2019-PR).

**Informed Consent Statement:** Informed consent was obtained from all human subjects involved in the study.

**Data Availability Statement:** Data are available upon reasonable request.

**Conflicts of Interest:** The authors declare no conflict of interest with regard to the present study.

## References

1. Casali, P.G.; Blay, J.Y.; Abecassis, N.; Bajpai, J.; Bauer, S.; Biagini, R.; Bielack, S.; Bonvalot, S.; Boukovinas, I.; Bovee, J.V.M.; et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **2022**, *33*, 20–33. [[CrossRef](#)] [[PubMed](#)]
2. Van der Graaf, W.T.A.; Tielen, R.; Bonenkamp, J.J.; Lemmens, V.; Verhoeven, R.H.A.; de Wilt, J.H.W. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. *Br. J. Surg.* **2018**, *105*, 1020–1027. [[CrossRef](#)] [[PubMed](#)]
3. Søreide, K.; Sandvik, O.M.; Søreide, J.A.; Giljaca, V.; Jureckova, A.; Bulusu, V.R. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. *Cancer Epidemiol.* **2016**, *40*, 39–46. [[CrossRef](#)] [[PubMed](#)]

4. Demetri, G.D.; von Mehren, M.; Blanke, C.D.; Van den Abbeele, A.D.; Eisenberg, B.; Roberts, P.J.; Heinrich, M.C.; Tuveson, D.A.; Singer, S.; Janicek, M.; et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N. Engl. J. Med.* **2002**, *347*, 472–480. [[CrossRef](#)] [[PubMed](#)]
5. Joensuu, H.; Roberts, P.J.; Sarlomo-Rikala, M.; Andersson, L.C.; Tervahartiala, P.; Tuveson, D.; Silberman, S.; Capdeville, R.; Dimitrijevic, S.; Druker, B.; et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *N. Engl. J. Med.* **2001**, *344*, 1052–1056. [[CrossRef](#)] [[PubMed](#)]
6. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N. Engl. J. Med.* **2001**, *344*, 1031–1037. [[CrossRef](#)]
7. Martin-Broto, J.; Martinez-Marín, V.; Serrano, C.; Hindi, N.; López-Guerrero, J.A.; Bisculua, M.; Ramos-Asensio, R.; Vallejo-Benítez, A.; Marcilla-Plaza, D.; González-Cámpora, R. Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. *Clin. Transl. Oncol.* **2017**, *19*, 536–545. [[CrossRef](#)]
8. Corless, C.L.; Barnett, C.M.; Heinrich, M.C. Gastrointestinal stromal tumours: Origin and molecular oncology. *Nat. Rev. Cancer* **2011**, *11*, 865–878. [[CrossRef](#)]
9. Miettinen, M.; Lasota, J. Histopathology of gastrointestinal stromal tumor. *J. Surg. Oncol.* **2011**, *104*, 865–873. [[CrossRef](#)]
10. Rossi, S.; Gasparotto, D.; Miceli, R.; Toffolatti, L.; Gallina, G.; Scaramel, E.; Marzotto, A.; Boscato, E.; Messerini, L.; Bearzi, I.; et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: A population-based study. *Am. J. Surg. Pathol.* **2015**, *39*, 922–930. [[CrossRef](#)]
11. Huss, S.; Pasternack, H.; Ihle, M.A.; Merkelbach-Bruse, S.; Heitkötter, B.; Hartmann, W.; Trautmann, M.; Gevensleben, H.; Büttner, R.; Schildhaus, H.U.; et al. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFR $\alpha$  wild-type GISTs are rare events. *Hum. Pathol.* **2017**, *62*, 206–214. [[CrossRef](#)]
12. Kalfusova, A.; Linke, Z.; Kalinova, M.; Krskova, L.; Hilska, I.; Szabova, J.; Vicha, A.; Kodet, R. Gastrointestinal stromal tumors—Summary of mutational status of the primary/secondary KIT/PDGFR $\alpha$  mutations, BRAF mutations and SDH defects. *Pathol. Res. Pract.* **2019**, *215*, 152708. [[CrossRef](#)]
13. Patel, S.R.; Reichardt, P. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. *Cancer* **2021**, *127*, 2187–2195. [[CrossRef](#)]
14. Tan, Y.; Trent, J.C.; Wilky, B.A.; Kerr, D.A.; Rosenberg, A.E. Current status of immunotherapy for gastrointestinal stromal tumor. *Cancer Gene Ther.* **2017**, *24*, 130–133. [[CrossRef](#)]
15. Vallilas, C.; Sarantis, P.; Kyriazoglou, A.; Koustas, E.; Theocharis, S.; Papavassiliou, A.G.; Karamouzis, M.V. Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules. *Int. J. Mol. Sci.* **2021**, *22*, 493. [[CrossRef](#)]
16. Arshad, J.; Costa, P.A.; Barreto-Coelho, P.; Valdes, B.N.; Trent, J.C. Immunotherapy Strategies for Gastrointestinal Stromal Tumor. *Cancers* **2021**, *13*, 3525. [[CrossRef](#)]
17. Reilley, M.J.; Bailey, A.; Subbiah, V.; Janku, F.; Naing, A.; Falchook, G.; Karp, D.; Piha-Paul, S.; Tsimberidou, A.; Fu, S.; et al. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. *J. Immunother. Cancer* **2017**, *5*, 35. [[CrossRef](#)]
18. D’Angelo, S.P.; Shoushtari, A.N.; Keohan, M.L.; Dickson, M.A.; Gounder, M.M.; Chi, P.; Loo, J.K.; Gaffney, L.; Schneider, L.; Patel, Z.; et al. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. *Clin. Cancer Res.* **2017**, *23*, 2972–2980. [[CrossRef](#)]
19. Liu, M.; Etherington, M.S.; Hanna, A.; Medina, B.D.; Vitiello, G.A.; Bowler, T.G.; Param, N.J.; Levin, L.; Rossi, F.; DeMatteo, R.P. Oncogenic KIT Modulates Type I IFN-Mediated Antitumor Immunity in GIST. *Cancer Immunol. Res.* **2021**, *9*, 542–553. [[CrossRef](#)]
20. Cai, L.; Michelakos, T.; Yamada, T.; Fan, S.; Wang, X.; Schwab, J.H.; Ferrone, C.R.; Ferrone, S. Defective HLA class I antigen processing machinery in cancer. *Cancer Immunol. Immunother.* **2018**, *67*, 999–1009. [[CrossRef](#)]
21. Tieniber, A.D.; Hanna, A.N.; Medina, B.D.; Vitiello, G.A.; Etherington, M.S.; Liu, M.; Do, K.J.; Rossi, F.; DeMatteo, R.P. Tyrosine kinase inhibition alters intratumoral CD8<sup>+</sup> T-cell subtype composition and activity. *Cancer Immunol. Res.* **2022**. [[CrossRef](#)] [[PubMed](#)]
22. Singh, A.S.; Hecht, J.R.; Rosen, L.; Wainberg, Z.A.; Wang, X.; Douek, M.; Hagopian, A.; Andes, R.; Sauer, L.; Brackert, S.R.; et al. A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors. *Clin. Cancer Res.* **2022**, *28*, 84–94. [[CrossRef](#)] [[PubMed](#)]
23. Leuci, V.; Donini, C.; Grignani, G.; Rotolo, R.; Mesiano, G.; Fiorino, E.; Gammaitoni, L.; D’Ambrosio, L.; Merlini, A.; Landoni, E.; et al. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. *Clin. Cancer Res.* **2020**, *26*, 6321–6334. [[CrossRef](#)] [[PubMed](#)]
24. Mesiano, G.; Grignani, G.; Fiorino, E.; Leuci, V.; Rotolo, R.; D’Ambrosio, L.; Salfi, C.; Gammaitoni, L.; Giraudo, L.; Pisacane, A.; et al. Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. *Oncoimmunology* **2018**, *7*, e1465161. [[CrossRef](#)]
25. Sangiolo, D.; Mesiano, G.; Gammaitoni, L.; Aglietta, M.; Grignani, G. Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. *Oncoimmunology* **2014**, *3*, e28269. [[CrossRef](#)]

26. Sangiolo, D.; Mesiano, G.; Gammaitoni, L.; Leuci, V.; Todorovic, M.; Giraudo, L.; Cammarata, C.; Dell'Aglio, C.; D'Ambrosio, L.; Pisacane, A.; et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. *Cancer Res.* **2014**, *74*, 119–129. [[CrossRef](#)]
27. Gasparotto, D.; Sbaraglia, M.; Rossi, S.; Baldazzi, D.; Brenca, M.; Mondello, A.; Nardi, F.; Racanelli, D.; Cacciatore, M.; Paolo Dei Tos, A.; et al. Tumor genotype, location, and malignant potential shape the immunogenicity of primary untreated gastrointestinal stromal tumors. *JCI Insight* **2020**, *5*, e142560. [[CrossRef](#)]
28. Vitiello, G.A.; Bowler, T.G.; Liu, M.; Medina, B.D.; Zhang, J.Q.; Param, N.J.; Loo, J.K.; Goldfeder, R.L.; Chibon, F.; Rossi, F.; et al. Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. *J. Clin. Investig.* **2019**, *129*, 1863–1877. [[CrossRef](#)]
29. Chen, L.L.; Gouw, L.; Sabripour, M.; Hwu, W.J.; Benjamin, R.S. Combining targeted therapy with immunotherapy (interferon- $\alpha$ ): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies. *Oncoimmunology* **2012**, *1*, 773–776. [[CrossRef](#)]
30. Chen, L.L.; Chen, X.; Choi, H.; Sang, H.; Chen, L.C.; Zhang, H.; Gouw, L.; Andtbacka, R.H.; Chan, B.K.; Rodesch, C.K.; et al. Exploiting antitumor immunity to overcome relapse and improve remission duration. *Cancer Immunol. Immunother.* **2012**, *61*, 1113–1124. [[CrossRef](#)]
31. Narumi, K.; Udagawa, T.; Kondoh, A.; Kobayashi, A.; Hara, H.; Ikarashi, Y.; Ohnami, S.; Takeshita, F.; Ochiya, T.; Okada, T.; et al. In vivo delivery of interferon- $\alpha$  gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts. *Gene Ther.* **2012**, *19*, 34–48. [[CrossRef](#)]
32. Kadowaki, N.; Antonenko, S.; Lau, J.Y.; Liu, Y.J. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. *J. Exp. Med.* **2000**, *192*, 219–226. [[CrossRef](#)]
33. Bauer, S.; Hartmann, J.T.; de Wit, M.; Lang, H.; Grabellus, F.; Antoch, G.; Niebel, W.; Erhard, J.; Ebeling, P.; Zeth, M.; et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. *Int. J. Cancer* **2005**, *117*, 316–325. [[CrossRef](#)]
34. Seifert, A.M.; Zeng, S.; Zhang, J.Q.; Kim, T.S.; Cohen, N.A.; Beckman, M.J.; Medina, B.D.; Maltbaek, J.H.; Loo, J.K.; Crawley, M.H.; et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. *Clin. Cancer Res.* **2017**, *23*, 454–465. [[CrossRef](#)]
35. Zhao, R.; Song, Y.; Wang, Y.; Huang, Y.; Li, Z.; Cui, Y.; Yi, M.; Xia, L.; Zhuang, W.; Wu, X.; et al. PD-1/PD-L1 blockade rescue exhausted CD8<sup>+</sup> T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. *Cell Prolif.* **2019**, *52*, e12571. [[CrossRef](#)]
36. Bertucci, F.; Finetti, P.; Mamessier, E.; Pantaleo, M.A.; Astolfi, A.; Ostrowski, J.; Birnbaum, D. PDL1 expression is an independent prognostic factor in localized GIST. *Oncoimmunology* **2015**, *4*, e1002729. [[CrossRef](#)]
37. Desai, S.A.; Wang, X.; Noronha, E.J.; Zhou, Q.; Rebmann, V.; Grosse-Wilde, H.; Moy, F.J.; Powers, R.; Ferrone, S. Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. *J. Immunol.* **2000**, *165*, 3275–3283. [[CrossRef](#)]
38. Lampson, L.A.; Levy, R. Two populations of Ia-like molecules on a human B cell line. *J. Immunol.* **1980**, *125*, 293–299.